AUPH - Aurinia Pharmaceuticals Inc.
5.80 -0.04 (-0.68%)
Pre-Market: 7:04AM EDT
| Previous Close | 6.04 |
| Open | 6.04 |
| Bid | 5.80 x 3100 |
| Ask | 6.29 x 800 |
| Day's Range | 5.81 - 6.06 |
| 52 Week Range | 4.41 - 7.68 |
| Volume | 531,855 |
| Avg. Volume | 558,907 |
| Market Cap | 489.448M |
| Beta | 1.75 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.41 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.92 |
- Simply Wall St.•8 days ago
Breakeven On The Horizon For Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)
Aurinia Pharmaceuticals Inc’s (NASDAQ:AUPH): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada,Read More...
- Motley Fool•10 days ago
Here's Why Aurinia Pharmaceuticals Inc. Jumped 11% in May
Investors are excited about the potential for its lead drug to expand into additional diseases.
- GlobeNewswire•21 days ago
Factors of Influence in 2018, Key Indicators and Opportunity within Shinhan Financial Group, Aurinia Pharmaceuticals, Delphi Technologies, Green Plains Partners LP, Sprague Resources LP, and CRH — New Research Emphasizes Economic Growth
NEW YORK, June 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Shinhan ...
- ACCESSWIRE•last month
Free Stock Performance Review on Array BioPharma and Three More Biotech Industry
Losses were broad based as all sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Intra-Cellular Therapies Inc. (NASDAQ: ITCI), Argos Therapeutics Inc. (NASDAQ: ARGS), Array BioPharma Inc. (NASDAQ: ARRY), and Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH).
- Motley Fool•last month
Here's Why Aurinia Pharmaceuticals Inc. Is Surging Today
A planned expansion of its lead program has investors fired up.
- Simply Wall St.•last month
Will Aurinia Pharmaceuticals Inc’s (NASDAQ:AUPH) Earnings Grow In The Years Ahead?
In December 2017, Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) announced its most recent earnings update, which indicated that losses became smaller relative to the prrior year’s level as a result of recentRead More...
- Associated Press•last month
Aurinia: 1Q Earnings Snapshot
On a per-share basis, the Victoria, British Columbia-based company said it had a loss of 18 cents. The results missed Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
- Business Wire•last month
Aurinia Reports First Quarter Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. has released its financial results for the first quarter ended March 31, 2018. Amounts, unless specified otherwise, are expressed in U.S.
- Business Wire•last month
Aurinia Pharmaceuticals Recognizes World Lupus DayTM with Activities Focused on Raising Awareness of Lupus Nephritis
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP), a clinical stage biopharmaceutical company focused on the global immunology market, today announced its support for World Lupus DayTM with activities focused on raising awareness of lupus nephritis (LN). In honor of the day, Aurinia is collaborating with The Mighty, a digital health community created to empower and connect people facing health challenges and disabilities. The collaboration will raise awareness of lupus nephritis, a serious comorbidity associated with Systemic Lupus Erythematosus (SLE).
- Business Wire•2 months ago
Aurinia Pharmaceuticals to Release First Quarter 2018 Financial Results on May 10, 2018
Aurinia Pharmaceuticals Inc., today announced that it will release its first quarter 2018 financial results on Thursday, May 10, 2018, after the market closes.
- Business Wire•2 months ago
Aurinia to Present at the Bloom Burton & Co. Healthcare Investor Conference on May 3, 2018
Aurinia Pharmaceuticals Inc., today announced that Celia Economides, Vice President, Corporate and Public Affairs, will present at the Bloom Burton & Co. Healthcare Investor Conference on Thursday, May 3rd at 1:30pm EDT.
- Motley Fool•2 months ago
Don't Get Greedy With Aurinia Pharmaceuticals Stock
Aurinia might make investors a lot of money. But there's no guarantee.
- Simply Wall St.•2 months ago
April Growth Opportunities – Espial Group And More
Looking to enhance your portfolio with high-growth, financially-robust stocks, but not sure where you should even begin? Stocks such as Espial Group and Aurinia Pharmaceuticals are deemed to be superiorRead More...
- GlobeNewswire•2 months ago
New Research Coverage Highlights SINOPEC Shangai Petrochemical, Aurinia Pharmaceuticals, Valeant Pharmaceuticals International, NTT DOCOMO, Southern Missouri, and KNOT Offshore Partners LP — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, April 09, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- Business Wire•3 months ago
Aurinia Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
Aurinia Pharmaceuticals Inc., today announced it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference. The conference is being held on April 8-10 at the Le Meridien Beach Plaza Hotel in Monte Carlo, Monaco.
- ACCESSWIRE•3 months ago
Blog Exposure - Aclaris Therapeutics Shares Positive Update on Phase-2 Results after a 3-Month Follow-Up of A-101 45% Topical Solution
Stock Monitor: Aurinia Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 21, 2018 / Active-Investors.com has just released a free research report on Aclaris Therapeutics, Inc. (NASDAQ: ACRS ...
- ACCESSWIRE•3 months ago
Aurinia Pharmaceuticals, Voclosporin Updates, Analysts Target Price and 2018 Outlook
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
- Simply Wall St.•3 months ago
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Is Expected To Breakeven
Aurinia Pharmaceuticals Inc’s (NASDAQ:AUPH): Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the development of a therapeutic drug to treat autoimmune diseases in Canada and internationally. The US$447.14MRead More...
- Associated Press•3 months ago
Aurinia reports 4Q loss
The Victoria, British Columbia-based company said it had a loss of 4 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
- Business Wire•3 months ago
Aurinia Reports Fourth Quarter and Full Year 2017 Financial Results and Operational Highlights
Aurinia Pharmaceuticals Inc. has released its financial results for the fourth quarter and year ended December 31, 2017. Amounts, unless specified otherwise, are expressed in U.S.
- ACCESSWIRE•3 months ago
Aurinia Pharmaceuticals Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 15, 2018 / Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 15, 2018, at 4:30 PM Eastern ...
- Business Wire•4 months ago
Aurinia Pharmaceuticals to Release Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018
Aurinia Pharmaceuticals Inc., today announced that it will release its fourth quarter and full year 2017 financial results on Thursday, March 15, 2018, after the market closes.
- Business Wire•4 months ago
Aurinia Enhances Research, Development, and Scientific Expertise with the Appointment of Michael Hayden to its Board of Directors
Aurinia Pharmaceuticals Inc. , a clinical stage biopharmaceutical company focused on the global immunology market, today announced the appointment of Michael Hayden, CM OBC MB ChB PhD FRCP FRSC to its board of directors.
- Motley Fool•4 months ago
Could Aurinia Pharmaceuticals Be a Millionaire-Maker Stock?
This small-cap biotech could be on the edge of something big.
